trending Market Intelligence /marketintelligence/en/news-insights/trending/MH4UzJBV_pys3JR_0Afv-g2 content esgSubNav
In This List

Mallinckrodt sells nuclear imaging biz to IBA Molecular

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Mallinckrodt sells nuclear imaging biz to IBA Molecular

Mallinckrodt Public Ltd. Co. completed the sale of its global nuclear imaging business to IBA Molecular for about $690 million, before tax.

The purchase price consists of about $574 million of up-front consideration, the assumption of about $39 million of long-term obligations and about $77 million of contingent consideration.

Mallinckrodt's nuclear imaging operations include two manufacturing facilities and 800 employees across the globe. The entire workforce and the manufacturing facilities have been transferred to IBA Molecular.